Status:
COMPLETED
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Lead Sponsor:
Stanford University
Conditions:
Mouth Cancer
Lip Cancer
Eligibility:
All Genders
18+ years
Brief Summary
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (...
Eligibility Criteria
Inclusion
- Having a new diagnosis of Nasopharyngeal carcinoma.
- Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion
- Age \<18 since NPC is a very rare condition in this age group and may have a different biological behavior
- Patients who are unable to provide informed consents for themselves.
Key Trial Info
Start Date :
November 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00186433
Start Date
November 1 2001
End Date
June 1 2013
Last Update
May 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305